Dianthus Therapeutics (DNTH) vs Genmab A/S (GMAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Dianthus Therapeutics (DNTH) has outperformed Genmab A/S (GMAB) over the past year, gaining 144.6% versus a gain of 10.1%. Over five years, GMAB leads with a -18.9% price change compared with -21.2% for DNTH. Genmab A/S is the larger company by market cap ($22.17 billion vs $4.61 billion), about 4.8 times the size.
Genmab A/S converts more of its revenue into profit, with a net margin of 25.9% versus -7973.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNTH | GMAB |
|---|---|---|
| Share price | $82.43 | $36.05 |
| Market cap | $4.61B | $22.17B |
| 1-day change | -2.89% | -1.64% |
| YTD return | +105.97% | +17.05% |
| 1-year return | +144.61% | +10.11% |
| 5-year return | -21.17% | -18.86% |
| P/E ratio (TTM) | — | 28.39 |
| Forward P/E | — | 23.64 |
| EPS (TTM) | $-4.24 | $1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.04M | $3.72B |
| Revenue growth (YoY) | -67.35% | +19.19% |
| Net income (latest FY) | $-162.34M | $963.00M |
| Gross margin | — | 93.60% |
| Operating margin | -8739.34% | 28.63% |
| Net margin | -7973.33% | 25.89% |
| 52-week high | $117.88 | $40.17 |
| 52-week low | $32.22 | $23.62 |
| Distance from 52-week high | -30.07% | -10.26% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +70.81% | +19.89% |
| Average volume | 799.48K | 2.83M |
| Shares outstanding | 55.93M | 614.90M |
| Employees | 92 | 3,119 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Genmab A/S is about 4.8 times larger than Dianthus Therapeutics by market value ($22.17B vs $4.61B).
- DNTH has outperformed GMAB by 134.5 percentage points over the past year.
- Genmab A/S is more profitable, keeping 25.9 cents of every revenue dollar as net income versus -7973.3 cents for Dianthus Therapeutics.
- Genmab A/S grew revenue faster in its latest fiscal year (+19.19% vs -67.35%).
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Genmab A/S
GMAB stock →Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,119 employees
DNTH vs GMAB FAQ
Which is bigger, Dianthus Therapeutics or Genmab A/S?
Genmab A/S (GMAB) is larger, with a market capitalization of $22.17B compared with $4.61B for Dianthus Therapeutics (DNTH).
Which stock has performed better over the past year, DNTH or GMAB?
DNTH returned +144.61% over the past 12 months, compared with +10.11% for GMAB (price return, excluding dividends). Past performance does not predict future results.
Are Dianthus Therapeutics and Genmab A/S in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.